Chemify Raises $50 Million to Usher in a New Era of Digital Chemistry

Glasgow-based startup Chemify has raised more than $50 million in an oversubscribed Series B funding round, signaling a defining moment for the fusion of chemistry and artificial intelligence. The round was co-led by Wing Venture Capital and Insight Partners, with participation from 8VC, Triatomic Capital, Blueyard, Rockspring, and Eos. The financing will accelerate Chemify’s expansion of its “Chemputation” platform — a system that merges AI, robotics, and automation to digitize the creation of molecules.

Founded in 2022 as a University of Glasgow spinout, Chemify’s ambition is bold: to make chemistry programmable. Its platform enables the design and synthesis of molecules via digital instructions, transforming what was once an art form of human experimentation into a reproducible, automated science. CEO and founder Lee Cronin, a pioneer in digital chemistry, describes the company’s vision as “creating a digital backbone for all of chemistry,” one capable of designing and manufacturing any molecule on demand.

The Chemifarm Revolution

Earlier this year, Chemify unveiled its Chemifarm, a fully automated molecular factory that embodies the company’s approach to “chemistry as code.” The facility integrates advanced robotics, AI models, and a vast database of validated chemical reactions. Within this environment, molecules that once took months to design can be produced in days, guided by computational precision rather than human trial and error.

Chemify’s Chemifarm represents more than efficiency—it’s an architectural shift in how discovery happens. By linking physical chemistry with digital processes, the company eliminates the disconnect between molecular design and synthesis. Researchers can now instruct the Chemifarm to produce a compound using a digital recipe, allowing them to iterate and refine designs without leaving the computational workspace.

With the new funding, Chemify plans to replicate this model globally, establishing a network of digital chemistry hubs. These centers will support pharmaceutical, biotech, and materials science partners seeking on-demand molecular design and production. A new facility in Silicon Valley, led by Chief Technical Officer Mike Bell, will serve as the anchor for the company’s U.S. operations and strengthen its collaborations with partners across the tech and life sciences sectors.

Redefining How Molecules Are Made

For investors, Chemify’s appeal lies in its potential to standardize and scale molecular innovation. “Chemify’s technology uses automation and physical AI to turn chemical synthesis from an art into a programmable science,” said Ansuman Satpathy, Partner at Wing Venture Capital. “Their work has the potential to drive significant advancements in drug discovery and medicine.”

Aiden Aceves, Vice President at Insight Partners, echoed that sentiment, noting that Chemify’s approach represents “a paradigm shift for how medicinal chemistry is done today.” By ensuring that designed molecules can actually be synthesized—a challenge that frequently halts discovery pipelines—the company bridges a crucial gap between computational chemistry and real-world drug production.

Both Satpathy and Aceves will join Chemify’s Board of Directors, supporting its push to become the leading platform for digital chemistry worldwide.

A Convergence of AI, Robotics, and Chemistry

Chemify’s model aligns with the broader evolution of science toward automation-driven discovery. Traditional chemistry relies heavily on human expertise and manual experimentation—a process that limits scalability and reproducibility. Chemify’s platform integrates machine learning models trained on large reaction datasets to predict viable synthesis pathways. Once a molecule design is validated computationally, robotic systems execute the synthesis with microscopic precision, creating a seamless feedback loop between digital models and physical results.

This closed-loop approach accelerates the entire discovery pipeline. Instead of waiting weeks for results, scientists can test, refine, and reproduce molecules within hours. Over time, the data from each experiment feeds back into Chemify’s system, improving predictive accuracy and expanding its chemical knowledge base.

The long-term implications extend beyond pharmaceuticals. Chemify’s digital chemistry infrastructure could enable breakthroughs in materials science, energy storage, and semiconductor manufacturing—industries that depend on complex molecules and precise formulations.

The Future of Drug Discovery

If Chemify’s approach succeeds, the future of drug discovery may look radically different. Instead of screening millions of compounds manually, AI models could design the optimal molecule digitally, while automated systems synthesize and test it without human intervention. What used to take years—and cost billions—could be achieved in months.

This shift doesn’t eliminate the role of human chemists; it redefines it. Scientists will move from repetitive experimentation to higher-level problem solving—setting goals, interpreting data, and guiding AI toward promising areas of research. In this vision, chemistry becomes an iterative partnership between human insight and machine execution.

The broader pharmaceutical industry has long struggled with inefficiency: only a fraction of discovered molecules ever reach clinical testing, and even fewer make it to market. Platforms like Chemify’s could reduce that attrition rate by ensuring that every molecule designed can be synthesized, tested, and optimized in real time.

As the digital transformation of chemistry accelerates, Chemify’s “chemputation” may mark the start of a new scientific era—one where chemistry joins computing as a fully programmable discipline. If that vision holds, the discovery of tomorrow’s life-saving drugs could happen not in the lab, but in the cloud.